Myeloid cells' contribution is key in CRS pathophysiology induced by T-cell engagers in BRGSF-HIS model
BRGSF-HIS & myeloid cell compartment in CRS
T-cell engagers show high efficacy in B-cell malignancies. A high risk of immune-related adverse events, including cytokine release syndrome (CRS), is reported in patients treated with T-cell engagers due to on-target offsite effects. Thus, reliable and translational mouse models are required to predict potential safety issues and investigate their rescue. PBMC-reconstituted models are the most currently used as preclinical models to investigate CRS induction’ while CD34+ reconstituted ones are more rarely described for this application.
Related products
Catalogue product
Customized product
Scientific excellence
From model design to experimental results
Featured in 600+ scientific articles
Collaborative approach
Collaboration with 17 Top Pharmas,
170+ Biotechs and 380+ Academic Institutions
Robust validation data on catalog models
Generated with biopharma partners and in-house
Innovative technologies
and guaranteed freedom to operate
Easy access to models
Models with certified health status from professional breeders in US and Europe